癌症疫苗在冷性肿瘤中的应用:临床前景、挑战和机遇

Finn, O.J.; Khleif, S.N.; Herberman, R.B. The FDA guidance on therapeutic cancer vaccines: The need for revision to include preventive cancer vaccines or for a new guidance dedicated to them. Cancer Prev. Res. (Phila.), 2015, 8(11), 1011-1016.
[http://dx.doi.org/10.1158/1940-6207.CAPR-15-0234] [PMID: 26353948]

Bryan, J.T. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine, 2007, 25(16), 3001-3006.
[http://dx.doi.org/10.1016/j.vaccine.2007.01.013] [PMID: 17289220]

Vockerodt, M.; Yap, L-F.; Shannon-Lowe, C.; Curley, H.; Wei, W.; Vrzalikova, K.; Murray, P.G. The Epstein-Barr virus and the pathogenesis of lymphoma. J. Pathol., 2015, 235(2), 312-322.
[http://dx.doi.org/10.1002/path.4459] [PMID: 25294567]

Plosker, G.L. Sipuleucel-T: In metastatic castration-resistant prostate cancer. Drugs, 2011, 71(1), 101-108.
[http://dx.doi.org/10.2165/11206840-000000000-00000] [PMID: 21175243]

Hewitt, D.B.; Nissen, N.; Hatoum, H.; Musher, B.; Seng, J.; Coveler, A.L.; Al-Rajabi, R.; Yeo, C.J.; Leiby, B.; Banks, J. A phase 3 randomized clinical trial of chemotherapy with or without algenpantucel-l (hyperacute-pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer. Ann. Surg., 2020, 275(1), 45-53.
[http://dx.doi.org/10.1097/SLA.0000000000004669] [PMID: 33630475]

Angell, H.; Galon, J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr. Opin. Immunol., 2013, 25(2), 261-267.
[http://dx.doi.org/10.1016/j.coi.2013.03.004] [PMID: 23579076]

Ott, P.A.; Hu, Z.; Keskin, D.B.; Shukla, S.A.; Sun, J.; Bozym, D.J.; Zhang, W.; Luoma, A.; Giobbie-Hurder, A.; Peter, L.; Chen, C.; Olive, O.; Carter, T.A.; Li, S.; Lieb, D.J.; Eisenhaure, T.; Gjini, E.; Stevens, J.; Lane, W.J.; Javeri, I.; Nellaiappan, K.; Salazar, A.M.; Daley, H.; Seaman, M.; Buchbinder, E.I.; Yoon, C.H.; Harden, M.; Lennon, N.; Gabriel, S.; Rodig, S.J.; Barouch, D.H.; Aster, J.C.; Getz, G.; Wucherpfennig, K.; Neuberg, D.; Ritz, J.; Lander, E.S.; Fritsch, E.F.; Hacohen, N.; Wu, C.J. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature, 2017, 547(7662), 217-221.
[http://dx.doi.org/10.1038/nature22991] [PMID: 28678778]

Sahin, U.; Derhovanessian, E.; Miller, M.; Kloke, B.P.; Simon, P.; Löwer, M.; Bukur, V.; Tadmor, A.D.; Luxemburger, U.; Schrörs, B.; Omokoko, T.; Vormehr, M.; Albrecht, C.; Paruzynski, A.; Kuhn, A.N.; Buck, J.; Heesch, S.; Schreeb, K.H.; Müller, F.; Ortseifer, I.; Vogler, I.; Godehardt, E.; Attig, S.; Rae, R.; Breitkreuz, A.; Tolliver, C.; Suchan, M.; Martic, G.; Hohberger, A.; Sorn, P.; Diekmann, J.; Ciesla, J.; Waksmann, O.; Brück, A.K.; Witt, M.; Zillgen, M.; Rothermel, A.; Kasemann, B.; Langer, D.; Bolte, S.; Diken, M.; Kreiter, S.; Nemecek, R.; Gebhardt, C.; Grabbe, S.; Höller, C.; Utikal, J.; Huber, C.; Loquai, C.; Türeci, Ö. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature, 2017, 547(7662), 222-226.
[http://dx.doi.org/10.1038/nature23003] [PMID: 28678784]

Hilf, N.; Kuttruff-Coqui, S.; Frenzel, K.; Bukur, V. Stevanović, S.; Gouttefangeas, C.; Platten, M.; Tabatabai, G.; Dutoit, V.; van der Burg, S.H.; Thor Straten, P.; Martínez-Ricarte, F.; Ponsati, B.; Okada, H.; Lassen, U.; Admon, A.; Ottensmeier, C.H.; Ulges, A.; Kreiter, S.; von Deimling, A.; Skardelly, M.; Migliorini, D.; Kroep, J.R.; Idorn, M.; Rodon, J.; Piró, J.; Poulsen, H.S.; Shraibman, B.; McCann, K.; Mendrzyk, R.; Löwer, M.; Stieglbauer, M.; Britten, C.M.; Capper, D.; Welters, M.J.P.; Sahuquillo, J.; Kiesel, K.; Derhovanessian, E.; Rusch, E.; Bunse, L.; Song, C.; Heesch, S.; Wagner, C.; Kemmer-Brück, A.; Ludwig, J.; Castle, J.C.; Schoor, O.; Tadmor, A.D.; Green, E.; Fritsche, J.; Meyer, M.; Pawlowski, N.; Dorner, S.; Hoffgaard, F.; Rössler, B.; Maurer, D.; Weinschenk, T.; Reinhardt, C.; Huber, C.; Rammensee, H.G.; Singh-Jasuja, H.; Sahin, U.; Dietrich, P.Y.; Wick, W. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature, 2019, 565(7738), 240-245.
[http://dx.doi.org/10.1038/s41586-018-0810-y] [PMID: 30568303]

Keskin, D.B.; Anandappa, A.J.; Sun, J.; Tirosh, I.; Mathewson, N.D.; Li, S.; Oliveira, G.; Giobbie-Hurder, A.; Felt, K.; Gjini, E.; Shukla, S.A.; Hu, Z.; Li, L.; Le, P.M.; Allesøe, R.L.; Richman, A.R.; Kowalczyk, M.S.; Abdelrahman, S.; Geduldig, J.E.; Charbonneau, S.; Pelton, K.; Iorgulescu, J.B.; Elagina, L.; Zhang, W.; Olive, O.; McCluskey, C.; Olsen, L.R.; Stevens, J.; Lane, W.J.; Salazar, A.M.; Daley, H.; Wen, P.Y.; Chiocca, E.A.; Harden, M.; Lennon, N.J.; Gabriel, S.; Getz, G.; Lander, E.S.; Regev, A.; Ritz, J.; Neuberg, D.; Rodig, S.J.; Ligon, K.L.; Suvà, M.L.; Wucherpfennig, K.W.; Hacohen, N.; Fritsch, E.F.; Livak, K.J.; Ott, P.A.; Wu, C.J.; Reardon, D.A. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature, 2019, 565(7738), 234-239.
[http://dx.doi.org/10.1038/s41586-018-0792-9] [PMID: 30568305]

Subudhi, S.K.; Vence, L.; Zhao, H.; Blando, J.; Yadav, S.S.; Xiong, Q.; Reuben, A.; Aparicio, A.; Corn, P.G.; Chapin, B.F.; Pisters, L.L.; Troncoso, P.; Tidwell, R.S.; Thall, P.; Wu, C.J.; Zhang, J.; Logothetis, C.L.; Futreal, A.; Allison, J.P.; Sharma, P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci. Transl. Med., 2020, 12(537), eaaz3577.
[http://dx.doi.org/10.1126/scitranslmed.aaz3577] [PMID: 32238575]

Nemunaitis, J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev. Vaccines, 2005, 4(3), 259-274.
[http://dx.doi.org/10.1586/14760584.4.3.259] [PMID: 16026242]

Roy, S.; Sethi, T.K.; Taylor, D.; Kim, Y.J.; Johnson, D.B. Breakthrough concepts in immune-oncology: Cancer vaccines at the bedside. J. Leukoc. Biol., 2020, 108(4), 1455-1489.
[http://dx.doi.org/10.1002/JLB.5BT0420-585RR] [PMID: 32557857]

Chiang, C.L.; Kandalaft, L.E.; Tanyi, J.; Hagemann, A.R.; Motz, G.T.; Svoronos, N.; Montone, K.; Mantia-Smaldone, G.M.; Smith, L.; Nisenbaum, H.L.; Levine, B.L.; Kalos, M.; Czerniecki, B.J.; Torigian, D.A.; Powell, D.J., Jr; Mick, R.; Coukos, G. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: From bench to bedside. Clin. Cancer Res., 2013, 19(17), 4801-4815.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-1185] [PMID: 23838316]

Jinushi, M.; Hodi, F.S.; Dranoff, G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol. Rev., 2008, 222, 287-298.
[http://dx.doi.org/10.1111/j.1600-065X.2008.00618.x] [PMID: 18364009]

Sauter, B.; Albert, M.L.; Francisco, L.; Larsson, M.; Somersan, S.; Bhardwaj, N. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J. Exp. Med., 2000, 191(3), 423-434.
[http://dx.doi.org/10.1084/jem.191.3.423] [PMID: 10662788]

Thomas, A.M.; Santarsiero, L.M.; Lutz, E.R.; Armstrong, T.D.; Chen, Y-C.; Huang, L-Q.; Laheru, D.A.; Goggins, M.; Hruban, R.H.; Jaffee, E.M. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med., 2004, 200(3), 297-306.
[http://dx.doi.org/10.1084/jem.20031435] [PMID: 15289501]

Soiffer, R.; Hodi, F.S.; Haluska, F.; Jung, K.; Gillessen, S.; Singer, S.; Tanabe, K.; Duda, R.; Mentzer, S.; Jaklitsch, M.; Bueno, R.; Clift, S.; Hardy, S.; Neuberg, D.; Mulligan, R.; Webb, I.; Mihm, M.; Dranoff, G. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol., 2003, 21(17), 3343-3350.
[http://dx.doi.org/10.1200/JCO.2003.07.005] [PMID: 12947071]

Hege, K.M.; Jooss, K.; Pardoll, D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int. Rev. Immunol., 2006, 25(5-6), 321-352.
[http://dx.doi.org/10.1080/08830180600992498] [PMID: 17169779]

Le, D.T.; Picozzi, V.J.; Ko, A.H.; Wainberg, Z.A.; Kindler, H.; Wang-Gillam, A.; Oberstein, P.; Morse, M.A.; Zeh, H.J., III; Weekes, C.; Reid, T.; Borazanci, E.; Crocenzi, T.; LoConte, N.K.; Musher, B.; Laheru, D.; Murphy, A.; Whiting, C.; Nair, N.; Enstrom, A.; Ferber, S.; Brockstedt, D.G.; Jaffee, E.M. Results from a Phase IIb, randomized, multicenter study of GVAX pancreas and CRS-207 compared with chemotherapy in adults with previously treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Clin. Cancer Res., 2019, 25(18), 5493-5502.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-2992] [PMID: 31126960]

Lipson, E.J.; Sharfman, W.H.; Chen, S.; McMiller, T.L.; Pritchard, T.S.; Salas, J.T.; Sartorius-Mergenthaler, S.; Freed, I.; Ravi, S.; Wang, H.; Luber, B.; Sproul, J.D.; Taube, J.M.; Pardoll, D.M.; Topalian, S.L. Safety and immunologic correlates of melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J. Transl. Med., 2015, 13, 214.
[http://dx.doi.org/10.1186/s12967-015-0572-3] [PMID: 26143264]

Banchereau, J.; Steinman, R.M. Dendritic cells and the control of immunity. Nature, 1998, 392(6673), 245-252.
[http://dx.doi.org/10.1038/32588] [PMID: 9521319]

Kyte, J.A.; Kvalheim, G.; Aamdal, S.; Saebøe-Larssen, S.; Gaudernack, G. Preclinical full-scale evaluation of dendritic cells transfected with autologous tumor-mRNA for melanoma vaccination. Cancer Gene Ther., 2005, 12(6), 579-591.
[http://dx.doi.org/10.1038/sj.cgt.7700837] [PMID: 15818380]

McGovern, N.; Schlitzer, A.; Gunawan, M.; Jardine, L.; Shin, A.; Poyner, E.; Green, K.; Dickinson, R.; Wang, X.N.; Low, D.; Best, K.; Covins, S.; Milne, P.; Pagan, S.; Aljefri, K.; Windebank, M.; Miranda-Saavedra, D.; Larbi, A.; Wasan, P.S.; Duan, K.; Poidinger, M.; Bigley, V.; Ginhoux, F.; Collin, M.; Haniffa, M. Human dermal CD14⁺ cells are a transient population of monocyte-derived macrophages. Immunity, 2014, 41(3), 465-477.
[http://dx.doi.org/10.1016/j.immuni.2014.08.006] [PMID: 25200712]

Jonuleit, H.; Kühn, U.; Müller, G.; Steinbrink, K.; Paragnik, L.; Schmitt, E.; Knop, J.; Enk, A.H. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol., 1997, 27(12), 3135-3142.
[http://dx.doi.org/10.1002/eji.1830271209] [PMID: 9464798]

Schadendorf, D.; Ugurel, S.; Schuler-Thurner, B.; Nestle, F.O.; Enk, A.; Bröcker, E.B.; Grabbe, S.; Rittgen, W.; Edler, L.; Sucker, A.; Zimpfer-Rechner, C.; Berger, T.; Kamarashev, J.; Burg, G.; Jonuleit, H.; Tüttenberg, A.; Becker, J.C.; Keikavoussi, P.; Kämpgen, E.; Schuler, G. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed Dendritic Cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann. Oncol., 2006, 17(4), 563-570.
[http://dx.doi.org/10.1093/annonc/mdj138] [PMID: 16418308]

Beer, T.M.; Bernstein, G.T.; Corman, J.M.; Glode, L.M.; Hall, S.J.; Poll, W.L.; Schellhammer, P.F.; Jones, L.A.; Xu, Y.; Kylstra, J.W.; Frohlich, M.W. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin. Cancer Res., 2011, 17(13), 4558-4567.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-3223] [PMID: 21558406]

Small, E.J.; Schellhammer, P.F.; Higano, C.S.; Redfern, C.H.; Nemunaitis, J.J.; Valone, F.H.; Verjee, S.S.; Jones, L.A.; Hershberg, R.M. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol., 2006, 24(19), 3089-3094.
[http://dx.doi.org/10.1200/JCO.2005.04.5252] [PMID: 16809734]

Higano, C.S.; Schellhammer, P.F.; Small, E.J.; Burch, P.A.; Nemunaitis, J.; Yuh, L.; Provost, N.; Frohlich, M.W. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer, 2009, 115(16), 3670-3679.
[http://dx.doi.org/10.1002/cncr.24429] [PMID: 19536890]

Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; Xu, Y.; Frohlich, M.W.; Schellhammer, P.F. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med., 2010, 363(5), 411-422.
[http://dx.doi.org/10.1056/NEJMoa1001294] [PMID: 20818862]

Bais, P.; Namburi, S.; Gatti, D.M.; Zhang, X.; Chuang, J.H. CloudNeo: A cloud pipeline for identifying patient-specific tumor neoantigens. Bioinformatics, 2017, 33(19), 3110-3112.
[http://dx.doi.org/10.1093/bioinformatics/btx375] [PMID: 28605406]

Finn, O.J.; Edwards, R.P. Human papillomavirus vaccine for cancer prevention. N. Engl. J. Med., 2009, 361(19), 1899-1901.
[http://dx.doi.org/10.1056/NEJMe0907480] [PMID: 19890134]

Pleasance, E.D.; Cheetham, R.K.; Stephens, P.J.; McBride, D.J.; Humphray, S.J.; Greenman, C.D.; Varela, I.; Lin, M-L.; Ordóñez, G.R.; Bignell, G.R.; Ye, K.; Alipaz, J.; Bauer, M.J.; Beare, D.; Butler, A.; Carter, R.J.; Chen, L.; Cox, A.J.; Edkins, S.; Kokko-Gonzales, P.I.; Gormley, N.A.; Grocock, R.J.; Haudenschild, C.D.; Hims, M.M.; James, T.; Jia, M.; Kingsbury, Z.; Leroy, C.; Marshall, J.; Menzies, A.; Mudie, L.J.; Ning, Z.; Royce, T.; Schulz-Trieglaff, O.B.; Spiridou, A.; Stebbings, L.A.; Szajkowski, L.; Teague, J.; Williamson, D.; Chin, L.; Ross, M.T.; Campbell, P.J.; Bentley, D.R.; Futreal, P.A.; Stratton, M.R. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature, 2010, 463(7278), 191-196.
[http://dx.doi.org/10.1038/nature08658] [PMID: 20016485]

Kreiter, S.; Vormehr, M.; van de Roemer, N.; Diken, M.; Löwer, M.; Diekmann, J.; Boegel, S.; Schrörs, B.; Vascotto, F.; Castle, J.C.; Tadmor, A.D.; Schoenberger, S.P.; Huber, C.; Türeci, Ö.; Sahin, U. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature, 2015, 520(7549), 692-696.
[http://dx.doi.org/10.1038/nature14426] [PMID: 25901682]

Schumacher, T.N.; Schreiber, R.D. Neoantigens in cancer immunotherapy. Science, 2015, 348(6230), 69-74.
[http://dx.doi.org/10.1126/science.aaa4971] [PMID: 25838375]

Tay, B.Q.; Wright, Q.; Ladwa, R.; Perry, C.; Leggatt, G.; Simpson, F.; Wells, J.W.; Panizza, B.J.; Frazer, I.H.; Cruz, J.L.G. Evolution of cancer vaccines-challenges, achievements, and future directions. Vaccines (Basel), 2021, 9(5), 535.
[http://dx.doi.org/10.3390/vaccines9050535] [PMID: 34065557]

Schuster, H.; Peper, J.K.; Bösmüller, H-C.; Röhle, K.; Backert, L.; Bilich, T.; Ney, B.; Löffler, M.W.; Kowalewski, D.J.; Trautwein, N.; Rabsteyn, A.; Engler, T.; Braun, S.; Haen, S.P.; Walz, J.S.; Schmid-Horch, B.; Brucker, S.Y.; Wallwiener, D.; Kohlbacher, O.; Fend, F.; Rammensee, H.G. Stevanović, S.; Staebler, A.; Wagner, P. The immunopeptidomic landscape of ovarian carcinomas. Proc. Natl. Acad. Sci. USA, 2017, 114(46), E9942-E9951.
[http://dx.doi.org/10.1073/pnas.1707658114] [PMID: 29093164]

Corman, J.M.; Sercarz, E.E.; Nanda, N.K. Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin. Exp. Immunol., 1998, 114(2), 166-172.
[http://dx.doi.org/10.1046/j.1365-2249.1998.00678.x] [PMID: 9822272]

Klapper, L.N.; Kirschbaum, M.H.; Sela, M.; Yarden, Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res., 2000, 77, 25-79.
[http://dx.doi.org/10.1016/S0065-230X(08)60784-8] [PMID: 10549355]

Cheever, M.A.; Allison, J.P.; Ferris, A.S.; Finn, O.J.; Hastings, B.M.; Hecht, T.T.; Mellman, I.; Prindiville, S.A.; Viner, J.L.; Weiner, L.M.; Matrisian, L.M. The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res., 2009, 15(17), 5323-5337.
[http://dx.doi.org/10.1158/1078-0432.CCR-09-0737] [PMID: 19723653]

Rugo, H.S. Im, S.A.; Cardoso, F.; Cortés, J.; Curigliano, G.; Musolino, A.; Pegram, M.D.; Wright, G.S.; Saura, C.; Escrivá-de-Romaní, S.; De Laurentiis, M.; Levy, C.; Brown-Glaberman, U.; Ferrero, J.M.; de Boer, M.; Kim, S.B.; Petráková, K.; Yardley, D.A.; Freedman, O.; Jakobsen, E.H.; Kaufman, B.; Yerushalmi, R.; Fasching, P.A.; Nordstrom, J.L.; Bonvini, E.; Koenig, S.; Edlich, S.; Hong, S.; Rock, E.P.; Gradishar, W.J. Efficacy of margetuximab vs. trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial. JAMA Oncol., 2021, 7(4), 573-584.
[http://dx.doi.org/10.1001/jamaoncol.2020.7932] [PMID: 33480963]

Upton, R.; Banuelos, A.; Feng, D.; Biswas, T.; Kao, K.; McKenna, K.; Willingham, S.; Ho, P.Y.; Rosental, B.; Tal, M.C.; Raveh, T.; Volkmer, J.P.; Pegram, M.D.; Weissman, I.L. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc. Natl. Acad. Sci. USA, 2021, 118(29), e2026849118.
[http://dx.doi.org/10.1073/pnas.2026849118] [PMID: 34257155]

Melero, I.; Gaudernack, G.; Gerritsen, W.; Huber, C.; Parmiani, G.; Scholl, S.; Thatcher, N.; Wagstaff, J.; Zielinski, C.; Faulkner, I.; Mellstedt, H. Therapeutic vaccines for cancer: An overview of clinical trials. Nat. Rev. Clin. Oncol., 2014, 11(9), 509-524.
[http://dx.doi.org/10.1038/nrclinonc.2014.111] [PMID: 25001465]

Chamani, R.; Ranji, P.; Hadji, M.; Nahvijou, A.; Esmati, E.; Alizadeh, A.M. Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis. Eur. J. Pharmacol., 2018, 831, 87-93.
[http://dx.doi.org/10.1016/j.ejphar.2018.05.010] [PMID: 29753042]

Rodríguez-Ruiz, M.E.; Perez-Gracia, J.L.; Rodríguez, I.; Alfaro, C.; Oñate, C.; Pérez, G.; Gil-Bazo, I.; Benito, A.; Inogés, S.; López-Diaz de Cerio, A.; Ponz-Sarvise, M.; Resano, L.; Berraondo, P.; Barbés, B.; Martin-Algarra, S.; Gúrpide, A.; Sanmamed, M.F.; de Andrea, C.; Salazar, A.M.; Melero, I. Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients. Ann. Oncol., 2018, 29(5), 1312-1319.
[http://dx.doi.org/10.1093/annonc/mdy089] [PMID: 29554212]

Thomas, S.; Prendergast, G.C. Cancer vaccines: A brief overview. Methods Mol. Biol., 2016, 1403, 755-761.
[http://dx.doi.org/10.1007/978-1-4939-3387-7_43] [PMID: 27076165]

De Keersmaecker, B.; Claerhout, S.; Carrasco, J.; Bar, I.; Corthals, J.; Wilgenhof, S.; Neyns, B.; Thielemans, K. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: Link between T-cell activation and clinical responses in advanced melanoma. J. Immunother. Cancer, 2020, 8(1), e000329.
[http://dx.doi.org/10.1136/jitc-2019-000329] [PMID: 32114500]

Lopes, A.; Vandermeulen, G.; Préat, V. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J. Exp. Clin. Cancer Res., 2019, 38(1), 146.
[http://dx.doi.org/10.1186/s13046-019-1154-7] [PMID: 30953535]

Pardi, N.; Muramatsu, H.; Weissman, D.; Karikó, K. In vitro transcription of long RNA containing modified nucleosides. Methods Mol. Biol., 2013, 969, 29-42.
[http://dx.doi.org/10.1007/978-1-62703-260-5_2] [PMID: 23296925]

Papachristofilou, A.; Hipp, M.M.; Klinkhardt, U.; Früh, M.; Sebastian, M.; Weiss, C.; Pless, M.; Cathomas, R.; Hilbe, W.; Pall, G.; Wehler, T.; Alt, J.; Bischoff, H.; Geißler, M.; Griesinger, F.; Kallen, K.J.; Fotin-Mleczek, M.; Schröder, A.; Scheel, B.; Muth, A.; Seibel, T.; Stosnach, C.; Doener, F.; Hong, H.S.; Koch, S.D.; Gnad-Vogt, U.; Zippelius, A. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J. Immunother. Cancer, 2019, 7(1), 38.
[http://dx.doi.org/10.1186/s40425-019-0520-5] [PMID: 30736848]

Conry, R.M.; LoBuglio, A.F.; Wright, M.; Sumerel, L.; Pike, M.J.; Johanning, F.; Benjamin, R.; Lu, D.; Curiel, D.T. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res., 1995, 55(7), 1397-1400.
[PMID: 7882341]

Bonehill, A.; Van Nuffel, A.M.T.; Corthals, J.; Tuyaerts, S.; Heirman, C.; François, V.; Colau, D.; van der Bruggen, P.; Neyns, B.; Thielemans, K. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin. Cancer Res., 2009, 15(10), 3366-3375.
[http://dx.doi.org/10.1158/1078-0432.CCR-08-2982] [PMID: 19417017]

Bonaventura, P.; Shekarian, T.; Alcazer, V.; Valladeau-Guilemond, J.; Valsesia-Wittmann, S.; Amigorena, S.; Caux, C.; Depil, S. Cold tumors: A therapeutic challenge for immunotherapy. Front. Immunol., 2019, 10, 168.
[http://dx.doi.org/10.3389/fimmu.2019.00168] [PMID: 30800125]

Chen, D.S.; Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature, 2017, 541(7637), 321-330.
[http://dx.doi.org/10.1038/nature21349] [PMID: 28102259]

Hegde, P.S.; Karanikas, V.; Evers, S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res., 2016, 22(8), 1865-1874.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-1507] [PMID: 27084740]

Galon, J.; Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov., 2019, 18(3), 197-218.
[http://dx.doi.org/10.1038/s41573-018-0007-y] [PMID: 30610226]

Liu, Y-T.; Sun, Z-J. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics, 2021, 11(11), 5365-5386.
[http://dx.doi.org/10.7150/thno.58390] [PMID: 33859752]

Mortezaee, K. Immune escape: A critical hallmark in solid tumors. Life Sci., 2020, 258, 118110.
[http://dx.doi.org/10.1016/j.lfs.2020.118110] [PMID: 32698074]

Buchbinder, E.I.; Desai, A. CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol., 2016, 39(1), 98-106.
[http://dx.doi.org/10.1097/COC.0000000000000239] [PMID: 26558876]

Fehrenbacher, L.; Spira, A.; Ballinger, M.; Kowanetz, M.; Vansteenkiste, J.; Mazieres, J.; Park, K.; Smith, D.; Artal-Cortes, A.; Lewanski, C.; Braiteh, F.; Waterkamp, D.; He, P.; Zou, W.; Chen, D.S.; Yi, J.; Sandler, A.; Rittmeyer, A. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet, 2016, 387(10030), 1837-1846.
[http://dx.doi.org/10.1016/S0140-6736(16)00587-0] [PMID: 26970723]

Tumeh, P.C.; Harview, C.L.; Yearley, J.H.; Shintaku, I.P.; Taylor, E.J.; Robert, L.; Chmielowski, B.; Spasic, M.; Henry, G.; Ciobanu, V.; West, A.N.; Carmona, M.; Kivork, C.; Seja, E.; Cherry, G.; Gutierrez, A.J.; Grogan, T.R.; Mateus, C.; Tomasic, G.; Glaspy, J.A.; Emerson, R.O.; Robins, H.; Pierce, R.H.; Elashoff, D.A.; Robert, C.; Ribas, A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 2014, 515(7528), 568-571.
[http://dx.doi.org/10.1038/nature13954] [PMID: 25428505]

Tekpli, X.; Lien, T.; Røssevold, A.H.; Nebdal, D.; Borgen, E.; Ohnstad, H.O.; Kyte, J.A.; Vallon-Christersson, J.; Fongaard, M.; Due, E.U.; Svartdal, L.G.; Sveli, M.A.T.; Garred, Ø.; Frigessi, A.; Sahlberg, K.K.; Sørlie, T.; Russnes, H.G.; Naume, B.; Kristensen, V.N. An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. Nat. Commun., 2019, 10(1), 5499.
[http://dx.doi.org/10.1038/s41467-019-13329-5] [PMID: 31796750]

Nishide, S.; Matsunaga, S.; Shiota, M.; Yamaguchi, T.; Kitajima, S.; Maekawa, Y.; Takeda, N.; Tomura, M.; Uchida, J.; Miura, K.; Nakatani, T.; Tomita, S. Controlling the phenotype of tumor-infiltrating macrophages via the PHD-HIF axis inhibits tumor growth in a mouse model. iScience, 2019, 19, 940-954.
[http://dx.doi.org/10.1016/j.isci.2019.08.033] [PMID: 31518902]

Singh, A.K.; McGuirk, J.P. CAR T cells: Continuation in a revolution of immunotherapy. Lancet Oncol., 2020, 21(3), e168-e178.
[http://dx.doi.org/10.1016/S1470-2045(19)30823-X] [PMID: 32135120]

Tanaka, A.; Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Cell Res., 2017, 27(1), 109-118.
[http://dx.doi.org/10.1038/cr.2016.151] [PMID: 27995907]

Müller, P.; Kreuzaler, M.; Khan, T.; Thommen, D.S.; Martin, K.; Glatz, K.; Savic, S.; Harbeck, N.; Nitz, U.; Gluz, O.; von Bergwelt-Baildon, M.; Kreipe, H.; Reddy, S.; Christgen, M.; Zippelius, A. Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci. Transl. Med., 2015, 7(315), 315ra188.
[http://dx.doi.org/10.1126/scitranslmed.aac4925] [PMID: 26606967]

Herbst, R.S.; Soria, J.C.; Kowanetz, M.; Fine, G.D.; Hamid, O.; Gordon, M.S.; Sosman, J.A.; McDermott, D.F.; Powderly, J.D.; Gettinger, S.N.; Kohrt, H.E.; Horn, L.; Lawrence, D.P.; Rost, S.; Leabman, M.; Xiao, Y.; Mokatrin, A.; Koeppen, H.; Hegde, P.S.; Mellman, I.; Chen, D.S.; Hodi, F.S. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 2014, 515(7528), 563-567.
[http://dx.doi.org/10.1038/nature14011] [PMID: 25428504]

Germano, G.; Lamba, S.; Rospo, G.; Barault, L.; Magrì, A.; Maione, F.; Russo, M.; Crisafulli, G.; Bartolini, A.; Lerda, G.; Siravegna, G.; Mussolin, B.; Frapolli, R.; Montone, M.; Morano, F.; de Braud, F.; Amirouchene-Angelozzi, N.; Marsoni, S.; D’Incalci, M.; Orlandi, A.; Giraudo, E.; Sartore-Bianchi, A.; Siena, S.; Pietrantonio, F.; Di Nicolantonio, F.; Bardelli, A. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature, 2017, 552(7683), 116-120.
[http://dx.doi.org/10.1038/nature24673] [PMID: 29186113]

Spranger, S.; Luke, J.J.; Bao, R.; Zha, Y.; Hernandez, K.M.; Li, Y.; Gajewski, A.P.; Andrade, J.; Gajewski, T.F. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc. Natl. Acad. Sci. USA, 2016, 113(48), E7759-E7768.
[http://dx.doi.org/10.1073/pnas.1609376113] [PMID: 27837020]

Luther, S.A.; Cyster, J.G. Chemokines as regulators of T cell differentiation. Nat. Immunol., 2001, 2(2), 102-107.
[http://dx.doi.org/10.1038/84205] [PMID: 11175801]

Montoya, M.; Schiavoni, G.; Mattei, F.; Gresser, I.; Belardelli, F.; Borrow, P.; Tough, D.F. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood, 2002, 99(9), 3263-3271.
[http://dx.doi.org/10.1182/blood.V99.9.3263] [PMID: 11964292]

Harlin, H.; Meng, Y.; Peterson, A.C.; Zha, Y.; Tretiakova, M.; Slingluff, C.; McKee, M.; Gajewski, T.F. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res., 2009, 69(7), 3077-3085.
[http://dx.doi.org/10.1158/0008-5472.CAN-08-2281] [PMID: 19293190]

Spranger, S.; Dai, D.; Horton, B.; Gajewski, T.F. Tumor-residing batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell, 2017, 31(5), 711-723.e4.
[http://dx.doi.org/10.1016/j.ccell.2017.04.003] [PMID: 28486109]

Peng, D.; Kryczek, I.; Nagarsheth, N.; Zhao, L.; Wei, S.; Wang, W.; Sun, Y.; Zhao, E.; Vatan, L.; Szeliga, W.; Kotarski, J.; Tarkowski, R.; Dou, Y.; Cho, K.; Hensley-Alford, S.; Munkarah, A.; Liu, R.; Zou, W. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature, 2015, 527(7577), 249-253.
[http://dx.doi.org/10.1038/nature15520] [PMID: 26503055]

Molon, B.; Ugel, S.; Del Pozzo, F.; Soldani, C.; Zilio, S.; Avella, D.; De Palma, A.; Mauri, P.; Monegal, A.; Rescigno, M.; Savino, B.; Colombo, P.; Jonjic, N.; Pecanic, S.; Lazzarato, L.; Fruttero, R.; Gasco, A.; Bronte, V.; Viola, A. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med., 2011, 208(10), 1949-1962.
[http://dx.doi.org/10.1084/jem.20101956] [PMID: 21930770]

Serra, S.; Vaisitti, T.; Audrito, V.; Bologna, C.; Buonincontri, R.; Chen, S-S.; Arruga, F.; Brusa, D.; Coscia, M.; Jaksic, O.; Inghirami, G.; Rossi, D.; Furman, R.R.; Robson, S.C.; Gaidano, G.; Chiorazzi, N.; Deaglio, S. Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Adv., 2016, 1(1), 47-61.
[http://dx.doi.org/10.1182/bloodadvances.2016000984] [PMID: 29296695]

Melief, C.J.; van Hall, T.; Arens, R.; Ossendorp, F.; van der Burg, S.H. Therapeutic cancer vaccines. J. Clin. Invest., 2015, 125(9), 3401-3412.
[http://dx.doi.org/10.1172/JCI80009] [PMID: 26214521]

Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol., 2010, 11(5), 373-384.
[http://dx.doi.org/10.1038/ni.1863] [PMID: 20404851]

Kober, J.; Leitner, J.; Klauser, C.; Woitek, R.; Majdic, O.; Stöckl, J.; Herndler-Brandstetter, D.; Grubeck-Loebenstein, B.; Reipert, B.M.; Pickl, W.F.; Pfistershammer, K.; Steinberger, P. The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells. Eur. J. Immunol., 2008, 38(10), 2678-2688.
[http://dx.doi.org/10.1002/eji.200838250] [PMID: 18825741]

Curtsinger, J.M.; Mescher, M.F. Inflammatory cytokines as a third signal for T cell activation. Curr. Opin. Immunol., 2010, 22(3), 333-340.
[http://dx.doi.org/10.1016/j.coi.2010.02.013] [PMID: 20363604]

Shi, S.; Zhu, H.; Xia, X.; Liang, Z.; Ma, X.; Sun, B. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine, 2019, 37(24), 3167-3178.
[http://dx.doi.org/10.1016/j.vaccine.2019.04.055] [PMID: 31047671]

Adamina, M.; Guller, U.; Bracci, L.; Heberer, M.; Spagnoli, G.C.; Schumacher, R. Clinical applications of virosomes in cancer immunotherapy. Expert Opin. Biol. Ther., 2006, 6(11), 1113-1121.
[http://dx.doi.org/10.1517/14712598.6.11.1113] [PMID: 17049010]

Banday, A.H.; Jeelani, S.; Hruby, V.J. Cancer vaccine adjuvants-recent clinical progress and future perspectives. Immunopharmacol. Immunotoxicol., 2015, 37(1), 1-11.
[http://dx.doi.org/10.3109/08923973.2014.971963] [PMID: 25318595]

Cusi, M.G. Applications of influenza virosomes as a delivery system. Hum. Vaccin., 2006, 2(1), 1-7.
[http://dx.doi.org/10.4161/hv.2.1.2494] [PMID: 17012895]

Wiedermann, U.; Wiltschke, C.; Jasinska, J.; Kundi, M.; Zurbriggen, R.; Garner-Spitzer, E.; Bartsch, R.; Steger, G.; Pehamberger, H.; Scheiner, O.; Zielinski, C.C. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: A phase I study. Breast Cancer Res. Treat., 2010, 119(3), 673-683.
[http://dx.doi.org/10.1007/s10549-009-0666-9] [PMID: 20092022]

Saupe, A.; McBurney, W.; Rades, T.; Hook, S. Immunostimulatory colloidal delivery systems for cancer vaccines. Expert Opin. Drug Deliv., 2006, 3(3), 345-354.
[http://dx.doi.org/10.1517/17425247.3.3.345] [PMID: 16640495]

Nakamura, T.; Yamazaki, D.; Yamauchi, J.; Harashima, H. The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration. J. Control. Release, 2013, 171(2), 216-224.
[http://dx.doi.org/10.1016/j.jconrel.2013.07.004] [PMID: 23860186]

Zhong, Z.; Wei, X.; Qi, B.; Xiao, W.; Yang, L.; Wei, Y.; Chen, L. A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice. Int. J. Pharm., 2010, 399(1-2), 156-162.
[http://dx.doi.org/10.1016/j.ijpharm.2010.07.053] [PMID: 20692327]

Neelapu, S.S.; Baskar, S.; Gause, B.L.; Kobrin, C.B.; Watson, T.M.; Frye, A.R.; Pennington, R.; Harvey, L.; Jaffe, E.S.; Robb, R.J.; Popescu, M.C.; Kwak, L.W. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen. Clin. Cancer Res., 2004, 10(24), 8309-8317.
[http://dx.doi.org/10.1158/1078-0432.CCR-04-1071] [PMID: 15623607]

Schnurr, M.; Orban, M.; Robson, N.C.; Shin, A.; Braley, H.; Airey, D.; Cebon, J.; Maraskovsky, E.; Endres, S. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J. Immunol., 2009, 182(3), 1253-1259.
[http://dx.doi.org/10.4049/jimmunol.182.3.1253] [PMID: 19155470]

Chen, Q.; Jackson, H.; Parente, P.; Luke, T.; Rizkalla, M.; Tai, T.Y.; Zhu, H.C.; Mifsud, N.A.; Dimopoulos, N.; Masterman, K.A.; Hopkins, W.; Goldie, H.; Maraskovsky, E.; Green, S.; Miloradovic, L.; McCluskey, J.; Old, L.J.; Davis, I.D.; Cebon, J.; Chen, W. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc. Natl. Acad. Sci. USA, 2004, 101(25), 9363-9368.
[http://dx.doi.org/10.1073/pnas.0403271101] [PMID: 15197261]

Davis, I.D.; Chen, W.; Jackson, H.; Parente, P.; Shackleton, M.; Hopkins, W.; Chen, Q.; Dimopoulos, N.; Luke, T.; Murphy, R.; Scott, A.M.; Maraskovsky, E.; McArthur, G.; MacGregor, D.; Sturrock, S.; Tai, T.Y.; Green, S.; Cuthbertson, A.; Maher, D.; Miloradovic, L.; Mitchell, S.V.; Ritter, G.; Jungbluth, A.A.; Chen, Y.T.; Gnjatic, S.; Hoffman, E.W.; Old, L.J.; Cebon, J.S. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc. Natl. Acad. Sci. USA, 2004, 101(29), 10697-10702.
[http://dx.doi.org/10.1073/pnas.0403572101] [PMID: 15252201]

Gin, D.Y.; Slovin, S.F. Enhancing immunogenicity of cancer vaccines: QS-21 as an immune adjuvant. Curr. Drug Ther., 2011, 6(3), 207-212.
[http://dx.doi.org/10.2174/157488511796391988] [PMID: 25473385]

Kim, S.K.; Ragupathi, G.; Cappello, S.; Kagan, E.; Livingston, P.O. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine, 2000, 19(4-5), 530-537.
[http://dx.doi.org/10.1016/S0264-410X(00)00195-X] [PMID: 11027818]

Slovin, S.F.; Ragupathi, G.; Musselli, C.; Fernandez, C.; Diani, M.; Verbel, D.; Danishefsky, S.; Livingston, P.; Scher, H.I. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: Clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol. Immunother., 2005, 54(7), 694-702.
[http://dx.doi.org/10.1007/s00262-004-0598-5] [PMID: 15726361]

HogenEsch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front. Immunol., 2012, 3, 406.
[http://dx.doi.org/10.3389/fimmu.2012.00406]

Marichal, T.; Ohata, K.; Bedoret, D.; Mesnil, C.; Sabatel, C.; Kobiyama, K.; Lekeux, P.; Coban, C.; Akira, S.; Ishii, K.J.; Bureau, F.; Desmet, C.J. DNA released from dying host cells mediates aluminum adjuvant activity. Nat. Med., 2011, 17(8), 996-1002.
[http://dx.doi.org/10.1038/nm.2403] [PMID: 21765404]

Kennedy, R.; Celis, E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev., 2008, 222, 129-144.
[http://dx.doi.org/10.1111/j.1600-065X.2008.00616.x] [PMID: 18363998]

Alfonso, S.; Valdés-Zayas, A.; Santiesteban, E.R.; Flores, Y.I.; Areces, F.; Hernández, M.; Viada, C.E.; Mendoza, I.C.; Guerra, P.P.; García, E.; Ortiz, R.A.; de la Torre, A.V.; Cepeda, M.; Pérez, K.; Chong, E.; Hernández, A.M.; Toledo, D.; González, Z.; Mazorra, Z.; Crombet, T.; Pérez, R.; Vázquez, A.M.; Macías, A.E. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin. Cancer Res., 2014, 20(14), 3660-3671.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-1674] [PMID: 24788102]

Aucouturier, J.; Dupuis, L.; Deville, S.; Ascarateil, S.; Ganne, V. Montanide ISA 720 and 51: A new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines, 2002, 1(1), 111-118.
[http://dx.doi.org/10.1586/14760584.1.1.111] [PMID: 12908518]

Hailemichael, Y.; Dai, Z.; Jaffarzad, N.; Ye, Y.; Medina, M.A.; Huang, X.F.; Dorta-Estremera, S.M.; Greeley, N.R.; Nitti, G.; Peng, W.; Liu, C.; Lou, Y.; Wang, Z.; Ma, W.; Rabinovich, B.; Sowell, R.T.; Schluns, K.S.; Davis, R.E.; Hwu, P.; Overwijk, W.W. Persistent antigen at vaccination sites induces tumor-specific CD8⁺ T cell sequestration, dysfunction and deletion. Nat. Med., 2013, 19(4), 465-472.
[http://dx.doi.org/10.1038/nm.3105] [PMID: 23455713]

Chianese-Bullock, K.A.; Pressley, J.; Garbee, C.; Hibbitts, S.; Murphy, C.; Yamshchikov, G.; Petroni, G.R.; Bissonette, E.A.; Neese, P.Y.; Grosh, W.W.; Merrill, P.; Fink, R.; Woodson, E.M.; Wiernasz, C.J.; Patterson, J.W.; Slingluff, C.L., Jr MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J. Immunol., 2005, 174(5), 3080-3086.
[http://dx.doi.org/10.4049/jimmunol.174.5.3080] [PMID: 15728523]

Neninger Vinageras, E.; de la Torre, A.; Osorio Rodríguez, M.; Catalá Ferrer, M.; Bravo, I.; Mendoza del Pino, M.; Abreu Abreu, D.; Acosta Brooks, S.; Rives, R.; del Castillo Carrillo, C.; González Dueñas, M.; Viada, C.; García Verdecia, B.; Crombet Ramos, T.; González Marinello, G.; Lage Dávila, A. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J. Clin. Oncol., 2008, 26(9), 1452-1458.
[http://dx.doi.org/10.1200/JCO.2007.11.5980] [PMID: 18349395]

Vono, M.; Taccone, M.; Caccin, P.; Gallotta, M.; Donvito, G.; Falzoni, S.; Palmieri, E.; Pallaoro, M.; Rappuoli, R.; Di Virgilio, F.; De Gregorio, E.; Montecucco, C.; Seubert, A. The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proc. Natl. Acad. Sci. USA, 2013, 110(52), 21095-21100.
[http://dx.doi.org/10.1073/pnas.1319784110] [PMID: 24324152]

Podda, A.; Del Giudice, G. MF59-adjuvanted vaccines: Increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines, 2003, 2(2), 197-203.
[http://dx.doi.org/10.1586/14760584.2.2.197] [PMID: 12899571]

Yang, M.; Yan, Y.; Fang, M.; Wan, M.; Wu, X.; Zhang, X.; Zhao, T.; Wei, H.; Song, D.; Wang, L.; Yu, Y. MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice. Int. Immunopharmacol., 2012, 13(4), 408-416.
[http://dx.doi.org/10.1016/j.intimp.2012.05.003] [PMID: 22595192]

Chan, G.C.F.; Chan, W.K.; Sze, D.M.Y. The effects of beta-glucan on human immune and cancer cells. J. Hematol. Oncol., 2009, 2, 25.
[http://dx.doi.org/10.1186/1756-8722-2-25] [PMID: 19515245]

Kaczanowska, S.; Joseph, A.M.; Davila, E. TLR agonists: Our best frenemy in cancer immunotherapy. J. Leukoc. Biol., 2013, 93(6), 847-863.
[http://dx.doi.org/10.1189/jlb.1012501] [PMID: 23475577]

Zitvogel, L.; Galluzzi, L.; Kepp, O.; Smyth, M.J.; Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol., 2015, 15, 405-414.

Asprodites, N.; Zheng, L.; Geng, D.; Velasco-Gonzalez, C.; Sanchez-Perez, L.; Davila, E. Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J., 2008, 22(10), 3628-3637.
[http://dx.doi.org/10.1096/fj.08-108274] [PMID: 18587008]

Zhang, Y.; Luo, F.; Cai, Y.; Liu, N.; Wang, L.; Xu, D.; Chu, Y. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J. Immunol., 2011, 186(4), 1963-1969.
[http://dx.doi.org/10.4049/jimmunol.1002320] [PMID: 21217015]

Salem, M.L.; El-Naggar, S.A.; Kadima, A.; Gillanders, W.E.; Cole, D.J. The adjuvant effects of the toll-like receptor 3 ligand polyinosinic-cytidylic acid poly (I:C) on antigen-specific CD8+ T cell responses are partially dependent on NK cells with the induction of a beneficial cytokine milieu. Vaccine, 2006, 24(24), 5119-5132.
[http://dx.doi.org/10.1016/j.vaccine.2006.04.010] [PMID: 16704888]

Kato, H.; Takeuchi, O.; Sato, S.; Yoneyama, M.; Yamamoto, M.; Matsui, K.; Uematsu, S.; Jung, A.; Kawai, T.; Ishii, K.J.; Yamaguchi, O.; Otsu, K.; Tsujimura, T.; Koh, C.S.; Reis e Sousa, C.; Matsuura, Y.; Fujita, T.; Akira, S. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature, 2006, 441(7089), 101-105.
[http://dx.doi.org/10.1038/nature04734] [PMID: 16625202]

Zhu, X.; Nishimura, F.; Sasaki, K.; Fujita, M.; Dusak, J.E.; Eguchi, J.; Fellows-Mayle, W.; Storkus, W.J.; Walker, P.R.; Salazar, A.M.; Okada, H. Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. J. Transl. Med., 2007, 5, 10.
[http://dx.doi.org/10.1186/1479-5876-5-10] [PMID: 17295916]

Chakravarty, J.; Kumar, S.; Trivedi, S.; Rai, V.K.; Singh, A.; Ashman, J.A.; Laughlin, E.M.; Coler, R.N.; Kahn, S.J.; Beckmann, A.M.; Cowgill, K.D.; Reed, S.G.; Sundar, S.; Piazza, F.M. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine, 2011, 29(19), 3531-3537.
[http://dx.doi.org/10.1016/j.vaccine.2011.02.096] [PMID: 21414377]

Fox, C.B.; Friede, M.; Reed, S.G.; Ireton, G.C. Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell. Biochem., 2010, 53, 303-321.
[http://dx.doi.org/10.1007/978-90-481-9078-2_14] [PMID: 20593273]

Cluff, C.W. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: Clinical results. Adv. Exp. Med. Biol., 2010, 667, 111-123.
[http://dx.doi.org/10.1007/978-1-4419-1603-7_10] [PMID: 20665204]

Coler, R.N.; Bertholet, S.; Moutaftsi, M.; Guderian, J.A.; Windish, H.P.; Baldwin, S.L.; Laughlin, E.M.; Duthie, M.S.; Fox, C.B.; Carter, D.; Friede, M.; Vedvick, T.S.; Reed, S.G. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One, 2011, 6(1), e16333.
[http://dx.doi.org/10.1371/journal.pone.0016333] [PMID: 21298114]

Krieg, A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov., 2006, 5(6), 471-484.
[http://dx.doi.org/10.1038/nrd2059] [PMID: 16763660]

de Titta, A.; Ballester, M.; Julier, Z.; Nembrini, C.; Jeanbart, L.; van der Vlies, A.J.; Swartz, M.A.; Hubbell, J.A. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc. Natl. Acad. Sci. USA, 2013, 110(49), 19902-19907.
[http://dx.doi.org/10.1073/pnas.1313152110] [PMID: 24248387]

Lin, A.Y.; Almeida, J.P.; Bear, A.; Liu, N.; Luo, L.; Foster, A.E.; Drezek, R.A. Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy. PLoS One, 2013, 8(5), e63550.
[http://dx.doi.org/10.1371/journal.pone.0063550] [PMID: 23691064]

Manegold, C.; Gravenor, D.; Woytowitz, D.; Mezger, J.; Hirsh, V.; Albert, G.; Al-Adhami, M.; Readett, D.; Krieg, A.M.; Leichman, C.G. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J. Clin. Oncol., 2008, 26(24), 3979-3986.
[http://dx.doi.org/10.1200/JCO.2007.12.5807] [PMID: 18711188]

Pashenkov, M.; Goëss, G.; Wagner, C.; Hörmann, M.; Jandl, T.; Moser, A.; Britten, C.M.; Smolle, J.; Koller, S.; Mauch, C.; Tantcheva-Poor, I.; Grabbe, S.; Loquai, C.; Esser, S.; Franckson, T.; Schneeberger, A.; Haarmann, C.; Krieg, A.M.; Stingl, G.; Wagner, S.N. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol., 2006, 24(36), 5716-5724.
[http://dx.doi.org/10.1200/JCO.2006.07.9129] [PMID: 17179105]

Gungor, B.; Yagci, F.C.; Tincer, G.; Bayyurt, B.; Alpdundar, E.; Yildiz, S.; Ozcan, M.; Gursel, I.; Gursel, M. CpG ODN nanorings induce IFNα from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity. Sci. Transl. Med., 2014, 6(235), 235ra61.
[http://dx.doi.org/10.1126/scitranslmed.3007909] [PMID: 24807558]

Morrow, M.P.; Yan, J.; Pankhong, P.; Ferraro, B.; Lewis, M.G.; Khan, A.S.; Sardesai, N.Y.; Weiner, D.B. Unique Th1/Th2 phenotypes induced during priming and memory phases by use of interleukin-12 (IL-12) or IL-28B vaccine adjuvants in rhesus macaques. Clin. Vaccine Immunol., 2010, 17(10), 1493-1499.
[http://dx.doi.org/10.1128/CVI.00181-10] [PMID: 20685940]

Green, D.R.; Ferguson, T.; Zitvogel, L.; Kroemer, G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol., 2009, 9, 353-363.

Galluzzi, L.; Vitale, I.; Aaronson, S.A.; Abrams, J.M.; Adam, D.; Agostinis, P.; Alnemri, E.S.; Altucci, L.; Amelio, I.; Andrews, D.W.; Annicchiarico-Petruzzelli, M.; Antonov, A.V.; Arama, E.; Baehrecke, E.H.; Barlev, N.A.; Bazan, N.G.; Bernassola, F.; Bertrand, M.J.M.; Bianchi, K.; Blagosklonny, M.V.; Blomgren, K.; Borner, C.; Boya, P.; Brenner, C.; Campanella, M.; Candi, E.; Carmona-Gutierrez, D.; Cecconi, F.; Chan, F.K.; Chandel, N.S.; Cheng, E.H.; Chipuk, J.E.; Cidlowski, J.A.; Ciechanover, A.; Cohen, G.M.; Conrad, M.; Cubillos-Ruiz, J.R.; Czabotar, P.E.; D’Angiolella, V.; Dawson, T.M.; Dawson, V.L.; De Laurenzi, V.; De Maria, R.; Debatin, K.M.; DeBerardinis, R.J.; Deshmukh, M.; Di Daniele, N.; Di Virgilio, F.; Dixit, V.M.; Dixon, S.J.; Duckett, C.S.; Dynlacht, B.D.; El-Deiry, W.S.; Elrod, J.W.; Fimia, G.M.; Fulda, S.; García-Sáez, A.J.; Garg, A.D.; Garrido, C.; Gavathiotis, E.; Golstein, P.; Gottlieb, E.; Green, D.R.; Greene, L.A.; Gronemeyer, H.; Gross, A.; Hajnoczky, G.; Hardwick, J.M.; Harris, I.S.; Hengartner, M.O.; Hetz, C.; Ichijo, H.; Jäättelä, M.; Joseph, B.; Jost, P.J.; Juin, P.P.; Kaiser, W.J.; Karin, M.; Kaufmann, T.; Kepp, O.; Kimchi, A.; Kitsis, R.N.; Klionsky, D.J.; Knight, R.A.; Kumar, S.; Lee, S.W.; Lemasters, J.J.; Levine, B.; Linkermann, A.; Lipton, S.A.; Lockshin, R.A.; López-Otín, C.; Lowe, S.W.; Luedde, T.; Lugli, E.; MacFarlane, M.; Madeo, F.; Malewicz, M.; Malorni, W.; Manic, G.; Marine, J.C.; Martin, S.J.; Martinou, J.C.; Medema, J.P.; Mehlen, P.; Meier, P.; Melino, S.; Miao, E.A.; Molkentin, J.D.; Moll, U.M.; Muñoz-Pinedo, C.; Nagata, S.; Nuñez, G.; Oberst, A.; Oren, M.; Overholtzer, M.; Pagano, M.; Panaretakis, T.; Pasparakis, M.; Penninger, J.M.; Pereira, D.M.; Pervaiz, S.; Peter, M.E.; Piacentini, M.; Pinton, P.; Prehn, J.H.M.; Puthalakath, H.; Rabinovich, G.A.; Rehm, M.; Rizzuto, R.; Rodrigues, C.M.P.; Rubinsztein, D.C.; Rudel, T.; Ryan, K.M.; Sayan, E.; Scorrano, L.; Shao, F.; Shi, Y.; Silke, J.; Simon, H.U.; Sistigu, A.; Stockwell, B.R.; Strasser, A.; Szabadkai, G.; Tait, S.W.G.; Tang, D.; Tavernarakis, N.; Thorburn, A.; Tsujimoto, Y.; Turk, B.; Vanden Berghe, T.; Vandenabeele, P.; Vander Heiden, M.G.; Villunger, A.; Virgin, H.W.; Vousden, K.H.; Vucic, D.; Wagner, E.F.; Walczak, H.; Wallach, D.; Wang, Y.; Wells, J.A.; Wood, W.; Yuan, J.; Zakeri, Z.; Zhivotovsky, B.; Zitvogel, L.; Melino, G.; Kroemer, G. Molecular mechanisms of cell death: Recommendations of the nomenclature committee on cell death 2018. Cell Death Differ., 2018, 25(3), 486-541.
[http://dx.doi.org/10.1038/s41418-017-0012-4] [PMID: 29362479]

Casares, N.; Pequignot, M.O.; Tesniere, A.; Ghiringhelli, F.; Roux, S.; Chaput, N.; Schmitt, E.; Hamai, A.; Hervas-Stubbs, S.; Obeid, M.; Coutant, F.; Métivier, D.; Pichard, E.; Aucouturier, P.; Pierron, G.; Garrido, C.; Zitvogel, L.; Kroemer, G. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med., 2005, 202(12), 1691-1701.
[http://dx.doi.org/10.1084/jem.20050915] [PMID: 16365148]

Chen, D.S.; Mellman, I. Oncology meets immunology: The cancer-immunity cycle. Immunity, 2013, 39, 1-10.

Yatim, N.; Albert, M.L. Dying to replicate: the orchestration of the viral life cycle, cell death pathways, and immunity. Immunity, 2011, 35(4), 478-490.
[http://dx.doi.org/10.1016/j.immuni.2011.10.010] [PMID: 22035840]

Sistigu, A.; Yamazaki, T.; Vacchelli, E.; Chaba, K.; Enot, D.P.; Adam, J.; Vitale, I.; Goubar, A.; Baracco, E.E.; Remédios, C.; Fend, L.; Hannani, D.; Aymeric, L.; Ma, Y.; Niso-Santano, M.; Kepp, O.; Schultze, J.L.; Tüting, T.; Belardelli, F.; Bracci, L.; La Sorsa, V.; Ziccheddu, G.; Sestili, P.; Urbani, F.; Delorenzi, M.; Lacroix-Triki, M.; Quidville, V.; Conforti, R.; Spano, J.P.; Pusztai, L.; Poirier-Colame, V.; Delaloge, S.; Penault-Llorca, F.; Ladoire, S.; Arnould, L.; Cyrta, J.; Dessoliers, M.C.; Eggermont, A.; Bianchi, M.E.; Pittet, M.; Engblom, C.; Pfirschke, C.; Préville, X.; Uzè, G.; Schreiber, R.D.; Chow, M.T.; Smyth, M.J.; Proietti, E.; André, F.; Kroemer, G.; Zitvogel, L. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med., 2014, 20(11), 1301-1309.
[http://dx.doi.org/10.1038/nm.3708] [PMID: 25344738]

Garg, A.D.; Vandenberk, L.; Fang, S.; Fasche, T.; Van Eygen, S.; Maes, J.; Van Woensel, M.; Koks, C.; Vanthillo, N.; Graf, N.; de Witte, P.; Van Gool, S.; Salven, P.; Agostinis, P. Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing. Cell Death Differ., 2017, 24(5), 832-843.
[http://dx.doi.org/10.1038/cdd.2017.15] [PMID: 28234357]

Vacchelli, E.; Ma, Y.; Baracco, E.E.; Sistigu, A.; Enot, D.P.; Pietrocola, F.; Yang, H.; Adjemian, S.; Chaba, K.; Semeraro, M.; Signore, M.; De Ninno, A.; Lucarini, V.; Peschiaroli, F.; Businaro, L.; Gerardino, A.; Manic, G.; Ulas, T.; Günther, P.; Schultze, J.L.; Kepp, O.; Stoll, G.; Lefebvre, C.; Mulot, C.; Castoldi, F.; Rusakiewicz, S.; Ladoire, S.; Apetoh, L.; Bravo-San Pedro, J.M.; Lucattelli, M.; Delarasse, C.; Boige, V.; Ducreux, M.; Delaloge, S.; Borg, C.; André, F.; Schiavoni, G.; Vitale, I.; Laurent-Puig, P.; Mattei, F.; Zitvogel, L.; Kroemer, G. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science, 2015, 350(6263), 972-978.
[http://dx.doi.org/10.1126/science.aad0779] [PMID: 26516201]

Obeid, M.; Tesniere, A.; Ghiringhelli, F.; Fimia, G.M.; Apetoh, L.; Perfettini, J.L.; Castedo, M.; Mignot, G.; Panaretakis, T.; Casares, N.; Métivier, D.; Larochette, N.; van Endert, P.; Ciccosanti, F.; Piacentini, M.; Zitvogel, L.; Kroemer, G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med., 2007, 13(1), 54-61.
[http://dx.doi.org/10.1038/nm1523] [PMID: 17187072]

Panaretakis, T.; Joza, N.; Modjtahedi, N.; Tesniere, A.; Vitale, I.; Durchschlag, M.; Fimia, G.M.; Kepp, O.; Piacentini, M.; Froehlich, K.U.; van Endert, P.; Zitvogel, L.; Madeo, F.; Kroemer, G. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ., 2008, 15(9), 1499-1509.
[http://dx.doi.org/10.1038/cdd.2008.67] [PMID: 18464797]

Fucikova, J.; Becht, E.; Iribarren, K.; Goc, J.; Remark, R.; Damotte, D.; Alifano, M.; Devi, P.; Biton, J.; Germain, C.; Lupo, A.; Fridman, W.H.; Dieu-Nosjean, M.C.; Kroemer, G.; Sautès-Fridman, C.; Cremer, I. Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res., 2016, 76(7), 1746-1756.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-1142] [PMID: 26842877]

Stoll, G.; Iribarren, K.; Michels, J.; Leary, A.; Zitvogel, L.; Cremer, I.; Kroemer, G. Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer. OncoImmunology, 2016, 5(7), e1177692.
[http://dx.doi.org/10.1080/2162402X.2016.1177692] [PMID: 27622029]

Bell, C.W.; Jiang, W.; Reich, C.F., III; Pisetsky, D.S. The extracellular release of HMGB1 during apoptotic cell death. Am. J. Physiol. Cell Physiol., 2006, 291(6), C1318-C1325.
[http://dx.doi.org/10.1152/ajpcell.00616.2005] [PMID: 16855214]

Faè, D.A.; Martorelli, D.; Mastorci, K.; Muraro, E.; Dal Col, J.; Franchin, G.; Barzan, L.; Comaro, E.; Vaccher, E.; Rosato, A.; Dolcetti, R. Broadening specificity and enhancing cytotoxicity of adoptive T cells for nasopharyngeal carcinoma immunotherapy. Cancer Immunol. Res., 2016, 4(5), 431-440.
[http://dx.doi.org/10.1158/2326-6066.CIR-15-0108] [PMID: 27009165]

Fucikova, J.; Kralikova, P.; Fialova, A.; Brtnicky, T.; Rob, L.; Bartunkova, J.; Spísek, R. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res., 2011, 71(14), 4821-4833.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-0950] [PMID: 21602432]

Martins, I.; Kepp, O.; Schlemmer, F.; Adjemian, S.; Tailler, M.; Shen, S.; Michaud, M.; Menger, L.; Gdoura, A.; Tajeddine, N.; Tesniere, A.; Zitvogel, L.; Kroemer, G. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene, 2011, 30(10), 1147-1158.
[http://dx.doi.org/10.1038/onc.2010.500] [PMID: 21151176]

Yamano, T.; Kubo, S.; Fukumoto, M.; Yano, A.; Mawatari-Furukawa, Y.; Okamura, H.; Tomita, N. Whole cell vaccination using immunogenic cell death by an oncolytic adenovirus is effective against a colorectal cancer model. Mol. Ther. Oncolytics, 2016, 3, 16031.
[http://dx.doi.org/10.1038/mto.2016.31] [PMID: 28035331]

Wen, C.C.; Chen, H.M.; Chen, S.S.; Huang, L.T.; Chang, W.T.; Wei, W.C.; Chou, L.C.; Arulselvan, P.; Wu, J.B.; Kuo, S.C.; Yang, N.S. Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines. J. Biomed. Sci., 2011, 18, 44.
[http://dx.doi.org/10.1186/1423-0127-18-44] [PMID: 21689407]

Mizumoto, N.; Tanaka, H.; Matsushima, H.; Vishwanath, M.; Takashima, A. Colchicine promotes antigen cross-presentation by murine dendritic cells. J. Invest. Dermatol., 2007, 127(6), 1543-1546.
[http://dx.doi.org/10.1038/sj.jid.5700699] [PMID: 17301837]

Woller, N.; Knocke, S.; Mundt, B.; Gürlevik, E.; Strüver, N.; Kloos, A.; Boozari, B.; Schache, P.; Manns, M.P.; Malek, N.P.; Sparwasser, T.; Zender, L.; Wirth, T.C.; Kubicka, S.; Kühnel, F. Virus-induced tumor inflammation facilitates effective DC cancer immunotherapy in a Treg-dependent manner in mice. J. Clin. Invest., 2011, 121(7), 2570-2582.
[http://dx.doi.org/10.1172/JCI45585] [PMID: 21646722]

Chen, H.M.; Wang, P.H.; Chen, S.S.; Wen, C.C.; Chen, Y.H.; Yang, W.C.; Yang, N.S. Shikonin induces immunogenic cell death in tumor cells and enhances dendritic cell-based cancer vaccine. Cancer Immunol. Immunother., 2012, 61(11), 1989-2002.
[http://dx.doi.org/10.1007/s00262-012-1258-9] [PMID: 22527248]

Lin, T.J.; Lin, H.T.; Chang, W.T.; Mitapalli, S.P.; Hsiao, P.W.; Yin, S.Y.; Yang, N.S. Shikonin-enhanced cell immunogenicity of tumor vaccine is mediated by the differential effects of DAMP components. Mol. Cancer, 2015, 14, 174.
[http://dx.doi.org/10.1186/s12943-015-0435-9] [PMID: 26403780]

Montico, B.; Lapenta, C.; Ravo, M.; Martorelli, D.; Muraro, E.; Zeng, B.; Comaro, E.; Spada, M.; Donati, S.; Santini, S.M.; Tarallo, R.; Giurato, G.; Rizzo, F.; Weisz, A.; Belardelli, F.; Dolcetti, R.; Dal Col, J. Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy. OncoImmunology, 2017, 6(11), e1356964.
[http://dx.doi.org/10.1080/2162402X.2017.1356964] [PMID: 29147614]

Gatti-Mays, M.E.; Redman, J.M.; Collins, J.M.; Bilusic, M. Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations. Hum. Vaccin. Immunother., 2017, 13(11), 2561-2574.
[http://dx.doi.org/10.1080/21645515.2017.1364322] [PMID: 28857666]

Finke, L.H.; Wentworth, K.; Blumenstein, B.; Rudolph, N.S.; Levitsky, H.; Hoos, A. Lessons from randomized phase III studies with active cancer immunotherapies-outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine, 2007, 25(Suppl. 2), B97-B109.
[http://dx.doi.org/10.1016/j.vaccine.2007.06.067] [PMID: 17916465]

van der Burg, S.H.; Arens, R.; Ossendorp, F.; van Hall, T.; Melief, C.J. Vaccines for established cancer: Overcoming the challenges posed by immune evasion. Nat. Rev. Cancer, 2016, 16(4), 219-233.
[http://dx.doi.org/10.1038/nrc.2016.16] [PMID: 26965076]

Hodge, J.W.; Garnett, C.T.; Farsaci, B.; Palena, C.; Tsang, K.Y.; Ferrone, S.; Gameiro, S.R. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int. J. Cancer, 2013, 133(3), 624-636.
[http://dx.doi.org/10.1002/ijc.28070] [PMID: 23364915]

Zitvogel, L.; Kroemer, G. Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. J. Clin. Invest., 2009, 119(8), 2127-2130.
[http://dx.doi.org/10.1172/JCI39991] [PMID: 19620780]

Emens, L.A.; Middleton, G. The interplay of immunotherapy and chemotherapy: Harnessing potential synergies. Cancer Immunol. Res., 2015, 3(5), 436-443.
[http://dx.doi.org/10.1158/2326-6066.CIR-15-0064] [PMID: 25941355]

Rettig, L.; Seidenberg, S.; Parvanova, I.; Samaras, P.; Curioni, A.; Knuth, A.; Pascolo, S. Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells. Int. J. Cancer, 2011, 129(4), 832-838.
[http://dx.doi.org/10.1002/ijc.25756] [PMID: 21710545]

Garnett, C.T.; Schlom, J.; Hodge, J.W. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: Effects of docetaxel on immune enhancement. Clin. Cancer Res., 2008, 14(11), 3536-3544.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-4025] [PMID: 18519787]

Chen, G.; Gupta, R.; Petrik, S.; Laiko, M.; Leatherman, J.M.; Asquith, J.M.; Daphtary, M.M.; Garrett-Mayer, E.; Davidson, N.E.; Hirt, K.; Berg, M.; Uram, J.N.; Dauses, T.; Fetting, J.; Duus, E.M.; Atay-Rosenthal, S.; Ye, X.; Wolff, A.C.; Stearns, V.; Jaffee, E.M.; Emens, L.A. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol. Res., 2014, 2(10), 949-961.
[http://dx.doi.org/10.1158/2326-6066.CIR-14-0058] [PMID: 25116755]

Harrop, R.; Chu, F.; Gabrail, N.; Srinivas, S.; Blount, D.; Ferrari, A. Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: A randomized phase II trial. Cancer Immunol. Immunother., 2013, 62(9), 1511-1520.
[http://dx.doi.org/10.1007/s00262-013-1457-z] [PMID: 23877659]

Dijkgraaf, E.M.; Santegoets, S.J.; Reyners, A.K.; Goedemans, R.; Nijman, H.W.; van Poelgeest, M.I.; van Erkel, A.R.; Smit, V.T.; Daemen, T.A.; van der Hoeven, J.J.; Melief, C.J.; Welters, M.J.; Kroep, J.R.; van der Burg, S.H. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer. Oncotarget, 2015, 6(31), 32228-32243.
[http://dx.doi.org/10.18632/oncotarget.4772] [PMID: 26334096]

Middleton, G.; Silcocks, P.; Cox, T.; Valle, J.; Wadsley, J.; Propper, D.; Coxon, F.; Ross, P.; Madhusudan, S.; Roques, T.; Cunningham, D.; Falk, S.; Wadd, N.; Harrison, M.; Corrie, P.; Iveson, T.; Robinson, A.; McAdam, K.; Eatock, M.; Evans, J.; Archer, C.; Hickish, T.; Garcia-Alonso, A.; Nicolson, M.; Steward, W.; Anthoney, A.; Greenhalf, W.; Shaw, V.; Costello, E.; Naisbitt, D.; Rawcliffe, C.; Nanson, G.; Neoptolemos, J. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomised, phase 3 trial. Lancet Oncol., 2014, 15(8), 829-840.
[http://dx.doi.org/10.1016/S1470-2045(14)70236-0] [PMID: 24954781]

Gameiro, S.R.; Jammeh, M.L.; Wattenberg, M.M.; Tsang, K.Y.; Ferrone, S.; Hodge, J.W. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget, 2014, 5(2), 403-416.
[http://dx.doi.org/10.18632/oncotarget.1719] [PMID: 24480782]

Chakraborty, M.; Abrams, S.I.; Camphausen, K.; Liu, K.; Scott, T.; Coleman, C.N.; Hodge, J.W. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J. Immunol., 2003, 170(12), 6338-6347.
[http://dx.doi.org/10.4049/jimmunol.170.12.6338] [PMID: 12794167]

Ferrara, T.A.; Hodge, J.W.; Gulley, J.L. Combining radiation and immunotherapy for synergistic antitumor therapy. Curr. Opin. Mol. Ther., 2009, 11(1), 37-42.
[PMID: 19169958]

Mineta, T.; Rabkin, S.D.; Yazaki, T.; Hunter, W.D.; Martuza, R.L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med., 1995, 1(9), 938-943.
[http://dx.doi.org/10.1038/nm0995-938] [PMID: 7585221]

Mesnil, M.; Yamasaki, H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication. Cancer Res., 2000, 60(15), 3989-3999.
[PMID: 10945596]

Pardoll, D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer, 2012, 12(4), 252-264.
[http://dx.doi.org/10.1038/nrc3239] [PMID: 22437870]

Dunn, G.P.; Bruce, A.T.; Ikeda, H.; Old, L.J.; Schreiber, R.D. Cancer immunoediting: From immunosurveillance to tumor escape. Nat. Immunol., 2002, 3(11), 991-998.
[http://dx.doi.org/10.1038/ni1102-991] [PMID: 12407406]

Hargadon, K.M.; Johnson, C.E.; Williams, C.J. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int. Immunopharmacol., 2018, 62, 29-39.
[http://dx.doi.org/10.1016/j.intimp.2018.06.001] [PMID: 29990692]

Dillman, R.O. Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors? Hum. Vaccin. Immunother., 2017, 13(3), 528-532.
[http://dx.doi.org/10.1080/21645515.2016.1244149] [PMID: 27808593]

Hurwitz, A.A.; Foster, B.A.; Kwon, E.D.; Truong, T.; Choi, E.M.; Greenberg, N.M.; Burg, M.B.; Allison, J.P. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res., 2000, 60(9), 2444-2448.
[PMID: 10811122]

Duraiswamy, J.; Kaluza, K.M.; Freeman, G.J.; Coukos, G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res., 2013, 73(12), 3591-3603.
[http://dx.doi.org/10.1158/0008-5472.CAN-12-4100] [PMID: 23633484]

Soares, K.C.; Rucki, A.A.; Wu, A.A.; Olino, K.; Xiao, Q.; Chai, Y.; Wamwea, A.; Bigelow, E.; Lutz, E.; Liu, L. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T cell infiltration into pancreatic tumors. J. Immunother. (Hagerstown, Md.: 1997), 2015, 38, 1.

Dranoff, G. GM-CSF-based cancer vaccines. Immunol. Rev., 2002, 188, 147-154.
[http://dx.doi.org/10.1034/j.1600-065X.2002.18813.x] [PMID: 12445288]

Gomez-Cambronero, J.; Horn, J.; Paul, C.C.; Baumann, M.A. Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: Involvement of the ribosomal p70 S6 kinase signaling pathway. J. Immunol., 2003, 171(12), 6846-6855.
[http://dx.doi.org/10.4049/jimmunol.171.12.6846] [PMID: 14662891]

Shi, Y.; Liu, C.H.; Roberts, A.I.; Das, J.; Xu, G.; Ren, G.; Zhang, Y.; Zhang, L.; Yuan, Z.R.; Tan, H.S.W.; Das, G.; Devadas, S. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: What we do and don’t know. Cell Res., 2006, 16(2), 126-133.
[http://dx.doi.org/10.1038/sj.cr.7310017] [PMID: 16474424]

Carmeliet, P.; Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature, 2011, 473(7347), 298-307.
[http://dx.doi.org/10.1038/nature10144] [PMID: 21593862]

Huang, Y.; Yuan, J.; Righi, E.; Kamoun, W.S.; Ancukiewicz, M.; Nezivar, J.; Santosuosso, M.; Martin, J.D.; Martin, M.R.; Vianello, F.; Leblanc, P.; Munn, L.L.; Huang, P.; Duda, D.G.; Fukumura, D.; Jain, R.K.; Poznansky, M.C. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. USA, 2012, 109(43), 17561-17566.
[http://dx.doi.org/10.1073/pnas.1215397109] [PMID: 23045683]

Bakos, O.; Lawson, C.; Rouleau, S.; Tai, L-H. Combining surgery and immunotherapy: Turning an immunosuppressive effect into a therapeutic opportunity. J. Immunother. Cancer, 2018, 6(1), 86.
[http://dx.doi.org/10.1186/s40425-018-0398-7] [PMID: 30176921]

Schirrmacher, V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory. Cancer Immunol. Immunother., 2005, 54(6), 587-598.
[http://dx.doi.org/10.1007/s00262-004-0602-0] [PMID: 15838708]

Bohle, W.; Schlag, P.; Liebrich, W.; Hohenberger, P.; Manasterski, M.; Möller, P.; Schirrmacher, V. Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus. Cancer, 1990, 66(7), 1517-1523.
[http://dx.doi.org/10.1002/1097-0142(19901001)66:7<1517:AID-CNCR2820660714>3.0.CO;2-I] [PMID: 2208003]

Pan, K.; Guan, X-X.; Li, Y-Q.; Zhao, J-J.; Li, J-J.; Qiu, H-J.; Weng, D-S.; Wang, Q-J.; Liu, Q.; Huang, L-X.; He, J.; Chen, S.P.; Ke, M.L.; Zeng, Y.X.; Xia, J.C. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with postmastectomy triple-negative breast cancer. Clin. Cancer Res., 2014, 20(11), 3003-3011.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-0082] [PMID: 24668644]